Literature DB >> 26537052

Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons.

Patricia A Boyle1, Lei Yu2, Sukriti Nag2, Sue Leurgans2, Robert S Wilson2, David A Bennett2, Julie A Schneider2.   

Abstract

OBJECTIVE: We tested the hypothesis that cerebral amyloid angiopathy (CAA) is related to Alzheimer disease (AD) dementia and decline in multiple cognitive systems in old age, independent of AD plaque and tangle pathology and other common age-related neuropathologies.
METHODS: Participants (n = 1,113) came from 2 longitudinal clinical-pathologic studies of aging, the Rush Memory and Aging Project and the Religious Orders Study. All underwent annual clinical evaluations including detailed cognitive testing for a mean of 7.1 years before death. Clinical diagnoses of AD were established after reviewing all clinical data, blinded to neuropathologic information. Neuropathologic examinations provided measures of CAA, AD pathology, macroscopic infarcts, microinfarcts, and neocortical Lewy bodies. The association of CAA with AD dementia was examined using logistic regression models, and its association with cognitive decline was examined using linear mixed models.
RESULTS: CAA was common, present in 78.9% of participants, and moderately related to AD pathology (ρ = 0.401, p < 0.0001). In analyses adjusted for plaques, tangles, and other common age-related neuropathologies, CAA was associated with an increased odds of AD dementia (odds ratio = 1.237, 95% confidence interval 1.082-1.414) and an increased rate of decline in global cognition, perceptual speed, episodic memory, and semantic memory. The associations of CAA with cognitive outcomes were not driven by the presence of capillary involvement.
CONCLUSIONS: CAA is an important determinant of AD dementia and decline in multiple cognitive systems in old age.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Year:  2015        PMID: 26537052      PMCID: PMC4664125          DOI: 10.1212/WNL.0000000000002175

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Risk factors for cerebral amyloid angiopathy in the elderly.

Authors:  Masahito Yamada
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

2.  Conscientiousness, dementia related pathology, and trajectories of cognitive aging.

Authors:  Robert S Wilson; Patricia A Boyle; Lei Yu; Eisuke Segawa; Joel Sytsma; David A Bennett
Journal:  Psychol Aging       Date:  2015-02-09

3.  Cognitive decline impairs financial and health literacy among community-based older persons without dementia.

Authors:  Patricia A Boyle; Lei Yu; Robert S Wilson; Eisuke Segawa; Aron S Buchman; David A Bennett
Journal:  Psychol Aging       Date:  2013-08-19

4.  Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology--a pilot study.

Authors:  Johannes Attems; Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2003-12-04       Impact factor: 17.088

5.  Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances.

Authors:  Dietmar Rudolf Thal; Estibaliz Capetillo-Zarate; Sergey Larionov; Matthias Staufenbiel; Stefan Zurbruegg; Nicolau Beckmann
Journal:  Neurobiol Aging       Date:  2008-03-21       Impact factor: 4.673

Review 6.  Amyloid angiopathy-related vascular cognitive impairment.

Authors:  Steven M Greenberg; M Edip Gurol; Jonathan Rosand; Eric E Smith
Journal:  Stroke       Date:  2004-09-30       Impact factor: 7.914

7.  The neuropathology of probable Alzheimer disease and mild cognitive impairment.

Authors:  Julie A Schneider; Zoe Arvanitakis; Sue E Leurgans; David A Bennett
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

8.  Staging and natural history of cerebrovascular pathology in dementia.

Authors:  V Deramecourt; J Y Slade; A E Oakley; R H Perry; P G Ince; C-A Maurage; R N Kalaria
Journal:  Neurology       Date:  2012-02-29       Impact factor: 9.910

9.  Development, appraisal, validation and implementation of a consensus protocol for the assessment of cerebral amyloid angiopathy in post-mortem brain tissue.

Authors:  Seth Love; Katy Chalmers; Paul Ince; Margaret Esiri; Johannes Attems; Kurt Jellinger; Masahito Yamada; Mark McCarron; Thais Minett; Fiona Matthews; Steven Greenberg; David Mann; Patrick Gavin Kehoe
Journal:  Am J Neurodegener Dis       Date:  2014-03-28

Review 10.  Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review.

Authors:  Hannah A D Keage; Roxanna O Carare; Robert P Friedland; Paul G Ince; Seth Love; James A Nicoll; Stephen B Wharton; Roy O Weller; Carol Brayne
Journal:  BMC Neurol       Date:  2009-01-13       Impact factor: 2.474

View more
  119 in total

1.  Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline.

Authors:  Patricia A Boyle; Jingyun Yang; Lei Yu; Sue E Leurgans; Ana W Capuano; Julie A Schneider; Robert S Wilson; David A Bennett
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

2.  Genetics of Gene Expression in the Aging Human Brain Reveal TDP-43 Proteinopathy Pathophysiology.

Authors:  Hyun-Sik Yang; Charles C White; Hans-Ulrich Klein; Lei Yu; Christopher Gaiteri; Yiyi Ma; Daniel Felsky; Sara Mostafavi; Vladislav A Petyuk; Reisa A Sperling; Nilüfer Ertekin-Taner; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  Neuron       Date:  2020-06-10       Impact factor: 17.173

Review 3.  Neuropsychological Effects of Cerebral Amyloid Angiopathy.

Authors:  Matthew Schrag; Howard Kirshner
Journal:  Curr Neurol Neurosci Rep       Date:  2016-08       Impact factor: 5.081

4.  Neuropsychological latent classes at enrollment and postmortem neuropathology.

Authors:  Andrea R Zammit; Charles B Hall; David A Bennett; Ali Ezzati; Mindy J Katz; Graciela Muniz-Terrera; Richard B Lipton
Journal:  Alzheimers Dement       Date:  2019-08-13       Impact factor: 21.566

Review 5.  Atypical Clinical Manifestations of Cerebral Amyloid Angiopathy.

Authors:  Carolyn Akers; Lealani May Y Acosta; Ciaran Considine; Daniel Claassen; Howard Kirshner; Matthew Schrag
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-27       Impact factor: 5.081

6.  Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease.

Authors:  Hiroko H Dodge; Jian Zhu; Randy Woltjer; Peter T Nelson; David A Bennett; Nigel J Cairns; David W Fardo; Jeffrey A Kaye; Deniz-Erten Lyons; Nora Mattek; Julie A Schneider; Lisa C Silbert; Chengjie Xiong; Lei Yu; Frederick A Schmitt; Richard J Kryscio; Erin L Abner
Journal:  Alzheimers Dement       Date:  2016-12-23       Impact factor: 21.566

7.  Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia.

Authors:  Thomas S Wingo; Jingjing Yang; Wen Fan; Se Min Canon; Ekaterina Sergeevna Gerasimov; Adriana Lori; Benjamin Logsdon; Bing Yao; Nicholas T Seyfried; James J Lah; Allan I Levey; Patricia A Boyle; Julia A Schneider; Philip L De Jager; David A Bennett; Aliza P Wingo
Journal:  NPJ Genom Med       Date:  2020-02-06       Impact factor: 8.617

8.  Postmortem brain MRI is related to cognitive decline, independent of cerebral vessel disease in older adults.

Authors:  Robert J Dawe; Lei Yu; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Patricia A Boyle
Journal:  Neurobiol Aging       Date:  2018-05-23       Impact factor: 4.673

9.  Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.

Authors:  Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

10.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.